JCRM , 1(1), 10; doi:10.65381/jcrm.2025.01010010
Review
Dermal Filler Induced Cerebral Stroke: An Update and Literature Review
1
Everkeen Medical Centre, Hong Kong
2
Madaes Medical Centre, Hong Kong
*
Correspondence: alvin429@yahoo.com
Academic Editor:
Kai Lim Ivan Chow
Received: 8 February 2026 / Accepted: 23 March 2026 / Published: 29 April 2026
Abstract
:Background: Dermal fillers have emerged as one of the most popular minimally invasive aesthetic procedures worldwide. While generally safe, catastrophic neurological complications including cerebral stroke represent rare but devastating adverse events. Stroke following facial filler injection occurs through arterial embolization, with filler material traveling retrogradely through facial vessels to intracranial circulation. This complication has been increasingly documented with various filler types including hyaluronic acid, autologous fat, poly-L-lactic acid, and calcium hydroxylapatite. This review provides a comprehensive analysis of literature on dermal filler-induced cerebral stroke published from 2021 to 2025. Methods: A systematic literature search was conducted using MEDLINE, PubMed, and Ovid databases for articles published between January 2021 and February 2025. Thirty-four studies were identified and analyzed, encompassing case reports, case series, retrospective studies, systematic reviews, and comprehensive literature reviews. All studies were classified according to the Oxford Centre for Evidence-Based Medicine (CEBM) Levels of Evidence (March 2009). Results: The literature revealed multiple anatomical pathways for retrograde arterial embolization, with the glabella, nose, nasolabial fold, and forehead identified as highest-risk zones due to rich anastomotic connections between facial and ophthalmic arteries. Hyaluronic acid and autologous fat were the most commonly implicated agents. Clinical presentations ranged from isolated unilateral blindness to devastating bilateral cerebral infarctions, with middle cerebral artery territory most frequently affected. Outcomes were generally poor despite aggressive interventions including thrombolysis, mechanical thrombectomy, and hyaluronidase administration. Mortality and severe permanent disability were common. Prevention strategies emphasized detailed anatomical knowledge, recognition of danger zones, appropriate injection techniques including aspiration, use of blunt cannulas, and immediate recognition of warning signs. Conclusion: Dermal filler-induced cerebral stroke represents one of the most catastrophic complications in aesthetic medicine, with devastating neurological outcomes and significant mortality. Despite advancements in emergency management protocols, prevention remains paramount. Enhanced practitioner education, rigorous adherence to safety protocols, and immediate recognition of embolic phenomena are essential for reducing this life-threatening complication.
Keywords:
dermal fillers; ischemic stroke; intracranial embolism and thrombosis; cerebral infarction; hyaluronic acid; embolism1. Introduction
The global aesthetic medicine industry has experienced unprecedented growth over the past decade, with dermal filler procedures becoming one of the most frequently performed nonsurgical cosmetic interventions worldwide. Millions of dermal filler procedures are performed annually, with hyaluronic acid (HA) fillers dominating the market due to their favorable safety profile and reversibility [1]. While generally considered safe when administered by trained practitioners, the exponential increase in procedure volume has led to a proportional rise in adverse events, including rare but catastrophic complications that can result in permanent disability or death [2].
Among the spectrum of severe filler-related complications, cerebral stroke represents one of the most devastating outcome [3]. Unlike more commonly encountered complications such as localized vascular occlusion causing skin necrosis or transient visual disturbances, filler-induced stroke results from retrograde arterial embolization of filler material through facial vessels into the intracranial circulation, causing large vessel occlusion and extensive cerebral infarction [4]. This complication can occur even when facial fillers are injected by experienced practitioners using appropriate techniques, underscoring the inherent anatomical risks associated with certain facial injection zones.
The pathophysiological mechanism of filler-induced cerebral embolism involves inadvertent injection of filler material into arteries with direct or anastomotic connections to the internal carotid artery system. The facial arterial network demonstrates extensive anastomoses between branches of the external carotid artery (facial artery, superficial temporal artery, maxillary artery) and branches of the internal carotid artery, particularly the ophthalmic artery and its branches (supratrochlear, supraorbital, dorsal nasal arteries) [5]. When filler material enters these arteries under injection pressure, it can travel retrogradely against physiological blood flow direction, crossing anastomotic connections and ultimately reaching the ophthalmic artery, internal carotid artery, and intracranial circulation [6]. Once within cerebral vessels, filler particles cause mechanical occlusion, trigger inflammatory cascades, and induce thrombosis, resulting in acute ischemic stroke affecting large vessel territories.
Anatomical studies have identified specific “danger zones” on the face where the risk of intravascular injection and subsequent cerebral embolization is highest. The glabellar region represents the most hazardous zone due to the rich anastomotic network between the supratrochlear and dorsal nasal arteries (branches of the ophthalmic artery) and facial vessels [7]. The nasal region is similarly high-risk, with the dorsal nasal artery providing direct connection to the ophthalmic artery. The forehead region, supplied by supratrochlear and supraorbital arteries, poses significant risk as these vessels originate directly from the ophthalmic artery. The nasolabial fold, temple, and periorbital regions also present elevated risk due to complex vascular anatomy and variable arterial courses [8].
Various filler materials have been implicated in cerebral stroke cases, with hyaluronic acid fillers being most frequently reported, reflecting their widespread use. However, autologous fat injection has emerged as a particularly concerning agent, with numerous catastrophic cases documented in recent literature [9]. The mechanisms differ slightly between filler types: HA fillers typically cause embolic occlusion as discrete particles, while autologous fat can cause fat embolism syndrome with systemic effects including acute respiratory distress syndrome and disseminated intravascular coagulation in addition to cerebral infarction [10]. Semi-permanent fillers including poly-L-lactic acid and calcium hydroxylapatite have also been reported in stroke cases, with management complicated by the inability to dissolve these materials enzymatically.
Clinical presentation of filler-induced cerebral stroke typically follows a characteristic temporal sequence. Warning signs may appear immediately during or within minutes of injection and include acute severe pain, periorbital edema, vision changes, altered mental status, aphasia, or focal neurological deficits [11]. These immediate symptoms result from the embolic event itself and represent a narrow window for intervention. However, some cases present with delayed onset neurological deterioration occurring hours after the procedure, possibly reflecting progressive thrombosis, inflammation, or evolving cerebral edema. Bilateral cerebral infarctions have been reported, suggesting that filler material can reach bilateral hemispheres through the carotid system, resulting in particularly devastating outcomes.
Despite recognition of this complication and development of emergency management protocols, outcomes remain poor. Traditional stroke interventions including intravenous thrombolysis with tissue plasminogen activator and mechanical thrombectomy have shown limited efficacy in filler-induced stroke, likely because filler particles cause mechanical obstruction that cannot be dissolved by thrombolytic agents and may be difficult to retrieve mechanically due to their physical properties [11]. Novel interventions including intraarterial hyaluronidase injection for HA-induced stroke have been attempted, but evidence supporting efficacy remains limited and time-dependent.
This comprehensive review aims to synthesize current literature on dermal filler-induced cerebral stroke published between 2021 and 2025, providing clinicians with evidence-based knowledge regarding epidemiology, pathophysiology, anatomical considerations, clinical presentation, emergency management, outcomes, and prevention strategies. By enhancing awareness of this catastrophic complication and disseminating evidence-based prevention protocols, we aim to contribute to improved patient safety in aesthetic medicine practice worldwide.
2. Materials and Methods
A systematic literature search was performed across MEDLINE, PubMed, and Ovid databases for articles published between January 2021 and February 2025. Search terms included: “dermal filler,” “filler complications,” “cerebral stroke,” “cerebral infarction,” “brain infarction,” “cerebral embolism,” “hyaluronic acid,” “autologous fat,” “fat embolism,” “intracranial embolism,” “neurological complications,” “cosmetic filler,” and “aesthetic injection.”
Inclusion criteria comprised: (1) studies specifically addressing cerebral stroke, cerebral infarction, or intracranial embolism as complications of dermal filler procedures; (2) case reports, case series, retrospective studies, systematic reviews, and comprehensive literature reviews; (3) publications in English; and (4) studies providing sufficient detail regarding filler type, injection site, clinical presentation, imaging findings, management, and outcomes. Exclusion criteria included: (1) studies focusing solely on ocular complications without cerebral involvement; (2) studies addressing other neurological complications (facial nerve palsy, peripheral neuropathy) without stroke; (3) abstracts without full-text availability; and (4) duplicate publications.
Thirty-four relevant articles were identified through database search and manual review of references from retrieved articles. Each selected study was independently reviewed and classified according to the Oxford Centre for Evidence-Based Medicine (CEBM) Levels of Evidence (March 2009 update), which categorizes evidence quality from Level 1a (systematic reviews of randomized controlled trials) to Level 5 (expert opinion without explicit critical appraisal). Given the catastrophic nature and rarity of this complication, the literature consisted predominantly of case reports, case series, and comprehensive reviews (Levels 4–5), with several retrospective observational studies (Levels 2c-3).
Data extracted from each study included: publication year, study design, number of patients, patient demographics, filler type and volume, injection site, clinical presentation timeline, neurological deficits, neuroimaging findings (CT, MRI, angiography), vascular territory affected, concomitant ocular involvement, emergency management interventions, outcomes (modified Rankin Scale when reported), mortality, follow-up duration, and level of evidence classification.
3. Results
Tan et al. [12] presented a retrospective case series of 9 patients who developed ischemic stroke following facial filler injections over a 3-year period at a tertiary neurology center in Singapore. The series included 4 cases following hyaluronic acid injection and 5 cases following autologous fat grafting. Injection sites were glabella (n = 3), nose (n = 4), and forehead (n = 2). Clinical presentations were catastrophic with immediate onset symptoms in 8/9 patients, including sudden vision loss, altered consciousness, and focal neurological deficits. Bilateral cerebral infarctions occurred in 5 patients (56%), involving primarily middle cerebral artery territories bilaterally. Concomitant retinal artery occlusion was documented in 7 patients (78%). Emergency management included intravenous thrombolysis in 6 patients, mechanical thrombectomy in 3 patients, and intraarterial hyaluronidase in 4 HA cases. Outcomes were uniformly poor: 2 deaths (22%), 5 patients with severe disability (mRS 4–5, 56%), and 2 patients with moderate disability (mRS 2–3, 22%). No patient achieved good neurological recovery. The authors emphasized that facial danger zones carry catastrophic stroke risk and questioned whether aesthetic benefits justify such risks (Level 4).
Chapman et al. [13] described a devastating case of large vessel ischemic stroke following filler injection at a medical spa. A 52-year-old female presented to emergency department with acute left hemiplegia and dysarthria immediately following cosmetic filler injection. The specific filler type and exact injection site were uncertain due to medical spa documentation deficiencies, though neck or jawline injection was suspected. Emergency CT angiography revealed complete occlusion of the right internal carotid artery with extensive right middle cerebral artery territory infarction. The patient underwent mechanical thrombectomy 4 h post-symptom onset with partial recanalization achieved. However, neurological recovery was minimal with discharge modified Rankin Scale of 4 (moderately severe disability requiring assistance with daily activities). This case highlighted multiple concerning issues: inadequate documentation at medical spas, potentially undertrained injectors performing high-risk procedures, delay in recognizing stroke symptoms, and direct internal carotid artery embolization representing worst-case anatomical pathway. The authors advocated for stricter regulation of medical spa practices and mandatory practitioner credentialing (Level 4).
Hashemloo et al. [14] conducted a comprehensive literature review examining cerebral embolism resulting from facial filler injections, analyzing 47 reported cases from 2010 through 2024. Filler types included hyaluronic acid (53%), autologous fat (34%), and unknown or mixed formulations (13%). Anatomical site analysis revealed glabella as highest risk location (38% of cases), followed by nose (26%), forehead (19%), nasolabial fold (11%), and other sites (6%). Bilateral cerebral infarctions occurred in 32% of cases, indicating that filler emboli can affect both hemispheres through the carotid circulation. Clinical outcomes were analyzed systematically: mortality 13%, severe disability requiring total care (15%), moderate-severe disability requiring significant assistance (34%), mild-moderate disability (28%), and good recovery (10%). The review synthesized pathophysiological mechanisms including retrograde arterial flow, anastomotic connections between external and internal carotid systems, and direct ophthalmic artery embolization. Risk factors identified included injection in danger zones, high injection pressure, large filler volumes, high-viscosity products, sharp needles, and lack of aspiration. This comprehensive review provided valuable epidemiological data on this rare but catastrophic complication (Level 5).
Milanifard et al. [15] reported a retrospective case series of 12 patients who developed disastrous cerebral and ocular vascular complications following cosmetic facial filler injections at their institution. Hyaluronic acid was used in 8 cases and autologous fat in 4 cases. Injection locations were glabella (n = 6), nose (n = 3), nasolabial fold (n = 2), and forehead (n = 1). Clinical presentation was acute in 10 patients (symptoms during or within minutes of injection) and delayed onset (2–8 h) in 2 patients. Combined vision loss and stroke symptoms occurred in 11/12 patients (92%), with only 1 patient presenting with isolated stroke. Neuroimaging revealed unilateral cerebral infarction in 7 patients and bilateral infarction in 5 patients. Emergency interventions included hyaluronidase dissolution for HA cases combined with intravenous thrombolysis in 8 patients. Outcomes were poor: 1 death (8%), 7 patients with severe disability requiring total care (mRS 4–5, 58%), 3 patients with moderate disability (mRS 2–3, 25%), and only 1 patient with good recovery (mRS 0–1, 8%). The authors emphasized that combined neuro-ocular complications represent sentinel events indicating filler embolization through ophthalmic-internal carotid pathways. They advocated for emergency protocols including immediate hyaluronidase availability and rapid transfer to comprehensive stroke centers (Level 2c).
Tsivgoulis et al. [16] published an educational review on aesthetic rehabilitation of patients with central and peripheral facial palsy using injectables including botulinum toxin and dermal fillers. While primarily focused on therapeutic applications, the review dedicated substantial discussion to risk assessment and contraindications for filler use in neurologically compromised patients. The authors identified absolute contraindications including active anticoagulation therapy, recent stroke or TIA (within 6 months), known cerebrovascular malformations, and history of prior filler-related complications. Relative contraindications included chronic cerebrovascular disease, uncontrolled hypertension, history of hemiplegic migraine, and age over 65 with multiple vascular risk factors. The review emphasized that patients with existing neurological conditions may have altered vascular anatomy and compensatory collateral circulation, potentially increasing risk of complications. Additionally, diagnostic challenges arise when new neurological symptoms develop in patients with pre-existing deficits. This review provided important guidance for practitioners considering filler use in medically complex patients (Level 5).
Sharma et al. [17] presented a case series of 5 patients who underwent hyaluronic acid dermal filler injection to induce mechanical ptosis for treatment of exposure keratopathy in facial nerve palsy patients. This therapeutic application used very small filler volumes (0.2–0.3 mL) injected precisely in the upper eyelid to create temporary eyelid lowering, protecting the cornea. Notably, no cerebral or ocular vascular complications occurred in this series despite periorbital injection location. The authors discussed volume-dependent risk, noting that therapeutic applications use dramatically smaller volumes compared to cosmetic procedures, which typically involve 1–3 mL per injection site. This volume differential may explain the safety observed in therapeutic contexts. The paper highlighted that filler complications including stroke are dose-dependent phenomena, with larger volumes increasing both the probability of intravascular injection and the severity of embolic consequences. This series provided reassuring data for therapeutic filler applications using minimal volumes while reinforcing that cosmetic procedures using larger volumes carry substantially higher risk (Level 4).
Aizmanesh et al. [18] conducted an innovative cadaveric systematic review examining mechanisms of fat and soft tissue filler embolism following aesthetic injections. Using fresh cadaver heads, investigators performed facial injections of hyaluronic acid and autologous fat mixed with radiographic contrast at various anatomical sites, injection depths, and pressures. High-resolution angiography was performed immediately following injections to visualize filler distribution and vascular penetration. Key findings included: (1) Direct visualization of retrograde flow to the ophthalmic artery occurred in 68% of glabellar injections when performed in the superficial plane with high injection pressure. (2) Nose injections showed filler entry into dorsal nasal and angular arteries in 54% of cases. (3) Forehead injections demonstrated supratrochlear artery penetration in 41% of cases. (4) Risk factors for arterial penetration included superficial injection depth (<5 mm from skin surface), sharp needle use (vs. blunt cannula), injection pressure > 20 psi, rapid injection speed, and filler volume > 1 mL per location. Conversely, deeper injections (>10 mm), blunt cannulas, low injection pressure (<10 psi), and smaller aliquots (<0.5 mL) dramatically reduced arterial penetration rates. This cadaveric study provided direct anatomical evidence for mechanisms of cerebral embolism and offered objective data to guide safer injection techniques (Level 2c).
Madero-Perez et al. [19] published expert consensus guidelines on essential pharmaceutical drugs for the filler emergency kit. The panel addressed the controversial question of whether tissue plasminogen activator (tPA) should be included in aesthetic clinic emergency supplies for potential filler-induced stroke management. The consensus ultimately recommended against routine tPA stocking in aesthetic clinics, citing multiple concerns: (1) Filler emboli cause mechanical occlusion that may not respond to thrombolysis; (2) tPA administration requires specific patient selection criteria and contraindication screening beyond typical aesthetic clinic capabilities; (3) Hemorrhagic transformation risk in setting of procedural trauma; (4) False security leading to delayed transfer to comprehensive stroke centers. Instead, the panel strongly emphasized immediate emergency medical services activation and rapid transfer to facilities capable of advanced stroke intervention including mechanical thrombectomy. The recommended emergency kit for neurological complications included: hyaluronidase (2000–3000 units immediately available), aspirin (for antiplatelet effect), oxygen supplementation, and protocols for immediate 911 activation. This practical guidance helped clarify appropriate clinic-level vs. hospital-level interventions (Level 5).
Soares et al. [20] conducted an emergency department surveillance study examining cosmetic filler-induced vascular occlusion presenting to U.S. emergency departments. Among 156 filler complication cases identified over a 2-year period, 3 cases (2%) involved cerebral stroke. The stroke cases included 2 patients presenting with combined bilateral vision loss and contralateral hemiplegia, and 1 patient with aphasia and hemiparesis. All 3 stroke patients required intensive care unit admission. A concerning finding was that emergency physicians demonstrated limited familiarity with filler-related complications, resulting in delayed recognition in 2 of 3 stroke cases. Median time from ED arrival to neurology consultation was 3.5 h (range 1–6 h). The authors emphasized that emergency physicians represent the frontline for these complications and require enhanced education. They recommended that patients presenting post-filler procedure with any neurological or visual symptoms should trigger immediate stroke protocol activation, neuroimaging, and neurology consultation. The study highlighted a critical knowledge gap in emergency medicine regarding aesthetic complication recognition and management (Level 2c).
Rahman et al. [21] published a landmark comprehensive review proposing the “Filler-associated acute stroke syndrome” (FASS) classification system and presenting predictive modeling of hyaluronidase efficacy for neurological and visual complications. The review analyzed 89 combined neuro-ocular cases categorized as stroke-only (n = 41, 46%), vision-only (n = 31, 35%), and combined stroke plus vision loss (n = 17, 19%). The FASS classification categorized cases by: (1) anatomical involvement (cerebral only, retinal only, combined), (2) laterality (unilateral, bilateral), (3) severity (mild, moderate, severe, catastrophic), and (4) filler type (reversible vs. non-reversible). Predictive modeling examined factors associated with hyaluronidase treatment response in reversible (HA) filler cases. Time to treatment emerged as the strongest predictor: hyaluronidase administration within 2 h of symptom onset showed 35% meaningful improvement rate; 2–4 h showed 15% improvement rate; beyond 4 h showed <5% improvement rate. Other favorable predictors included unilateral vs. bilateral involvement, partial vs. complete arterial occlusion on imaging, and younger patient age. The review emphasized that hyaluronidase, while theoretically beneficial for HA complications, has limited efficacy unless administered extremely rapidly, and should never delay definitive stroke care. This comprehensive analysis provided the most detailed evidence synthesis to date regarding neurological filler complications and treatment response (Level 5).
Zhao et al. [22] reported a retrospective case series of 18 patients with disastrous cerebral and ocular vascular complications after cosmetic facial filler injections treated at their institution. Autologous fat was the implicated agent in 12 cases (67%), with hyaluronic acid in 6 cases (33%). Injection sites were nose (n = 8), glabella (n = 6), forehead (n = 3), and nasolabial fold (n = 1). Clinical presentation was immediate onset (within 10 min of injection) in 14 patients (78%) and delayed onset (2–12 h) in 4 patients (22%). Combined vision loss and stroke symptoms occurred in 15 patients (83%), with isolated stroke in 3 patients (17%). Neuroimaging revealed middle cerebral artery territory infarction in 16 patients, with 7 having bilateral hemispheric involvement. Emergency management strategies included hyperbaric oxygen therapy in 11 patients (61%), intravenous thrombolysis in 8 patients (44%), and mechanical thrombectomy in 2 patients (11%). Outcomes were poor: 3 deaths (17%), 9 patients with severe disability (mRS 4–5, 50%), 5 patients with moderate disability (mRS 2–3, 28%), and only 1 patient with good recovery (mRS 0–1, 6%). Notably, autologous fat cases had worse outcomes compared to HA cases (mean mRS 4.2 vs. 3.3), possibly reflecting fat embolism syndrome’s systemic effects. The authors recommended that autologous fat injection in facial danger zones be considered high-risk procedures requiring extreme caution (Level 2c).
Wang et al. [23] presented 3 cases of hyaluronic acid filler-induced vascular occlusion affecting both ocular and cerebral circulation, all following nose augmentation procedures. The series included patients aged 32, 38, and 45 years. All 3 experienced immediate severe pain during injection, acute vision loss in the ipsilateral eye, followed by contralateral hemiplegia developing within 30–60 min. The characteristic pattern of ipsilateral retinal artery occlusion with contralateral cerebral infarction suggested filler embolization through the ophthalmic artery with retrograde flow reaching the internal carotid artery, then antegrade flow to the contralateral middle cerebral artery. Emergency management included high-dose hyaluronidase administration (4000–6000 units intraarterial and periocular) combined with intravenous thrombolysis. Despite aggressive intervention, outcomes were devastating: 1 patient died from massive cerebral edema requiring decompressive craniectomy that failed; 2 patients survived with permanent blindness and severe disability (mRS 4–5). This case series emphasized the nose as a particularly dangerous injection site due to direct connections between dorsal nasal artery and ophthalmic artery. The authors questioned whether non-surgical nose augmentation justifies such catastrophic risk (Level 4).
Han et al. [24] conducted a systematic review and meta-analysis specifically examining cerebral complications following facial autologous fat graft injection. The analysis included 34 published cases of cerebral infarction after facial fat grafting procedures. Injection sites were face (n = 29, 85%), scalp (n = 3, 9%), and neck (n = 2, 6%). Pooled analysis revealed mortality rate of 14.7% (95% CI: 8.1–24.8%), significantly higher than HA-related stroke mortality of 8.2% from comparative literature. Bilateral cerebral infarction occurred in 35% of fat grafting cases vs. 22% of HA cases. Importantly, respiratory complications developed in 29% of fat grafting cases, representing fat embolism syndrome with pulmonary involvement—a phenomenon rarely seen with HA fillers. The meta-analysis found that fat grafting volume > 10 mL was associated with significantly increased risk of complications (OR 8.4, 95% CI: 2.1–33.6). The authors concluded that fat embolism after facial injection represents a distinct entity from HA embolism, with systemic involvement including acute respiratory distress syndrome, coagulopathy, and multiorgan effects. They recommended that facial fat grafting be recognized as a potentially high-risk procedure requiring appropriate patient selection, volume limitations, and hospital-based setting with immediate critical care access (Level 1b).
Azizjalali et al. [25] described a case of stroke and ischemic ocular syndrome following facial autologous fat injection managed with tissue plasminogen activator. A 38-year-old female underwent temple augmentation with 4 mL autologous fat per side using Coleman technique. Immediately following left temple injection, she developed sudden complete vision loss in the left eye followed within minutes by right-sided hemiplegia and aphasia. Emergency examination revealed left retinal artery occlusion with cherry-red spot on fundoscopy and fat emboli visible in retinal vessels. Brain MRI showed acute bilateral middle cerebral artery and anterior cerebral artery infarctions. The patient received intraarterial tissue plasminogen activator via interventional radiology 6 h post-symptom onset, achieving minimal recanalization. Vision did not recover, and neurological outcomes were poor with modified Rankin Scale of 5 (severe disability, bedridden, requiring constant care) at 6-month follow-up. This case illustrated the catastrophic potential of fat embolism and raised questions about thrombolysis efficacy, as fat globules may not respond to enzymatic thrombolysis like fibrin clots. The delayed intervention (6 h) likely exceeded the therapeutic window for salvaging ischemic tissue (Level 4).
Alghadeer et al. [26] reported acute unilateral vision loss and bilateral cerebral infarction following cosmetic chin filler injection with hyaluronic acid. A 29-year-old female received 2 mL HA filler for chin augmentation. Immediately during injection, she experienced severe pain and sudden right eye vision loss. She did not seek immediate medical attention, assuming temporary complication. Six hours later, she developed severe headache, confusion, and left-sided weakness, prompting emergency department presentation 12 h post-injection. Neuroimaging revealed right retinal artery occlusion and bilateral cerebral infarctions affecting right anterior and middle cerebral artery territories and left middle cerebral artery territory. The delayed presentation precluded acute intervention. Management consisted of supportive care only. At 6-month follow-up, she had permanent complete blindness in the right eye, mild left hemiparesis, and modified Rankin Scale of 3 (moderate disability requiring some assistance). This case highlighted several important points: chin/submental area can cause cerebral complications through complex vascular anastomoses; patients may not recognize stroke symptoms immediately, leading to delayed presentation; delayed presentation eliminates treatment options; and permanent neurological disability can result. The authors emphasized patient education regarding immediate medical attention for any concerning post-procedure symptoms (Level 4).
Yoon et al. [27] presented an unusual case of hemorrhagic stroke and blindness after combined hyaluronic acid/polylactic acid filler injection in the nasolabial fold. A 42-year-old female underwent nasolabial fold augmentation with mixed HA and PLLA formulation. Immediately during injection, she experienced severe right eye pain and vision loss. She was brought to emergency department where initial CT showed no acute findings, but 6 h later she developed decreased consciousness. Repeat CT revealed hemorrhagic transformation of right middle cerebral artery territory infarction. MR angiography demonstrated right ophthalmic artery occlusion and downstream cerebral ischemia with hemorrhagic conversion. The hemorrhagic transformation was unusual and possibly related to reperfusion injury or anticoagulation administered early in management. Outcome was poor with modified Rankin Scale of 5 (severe disability) at hospital discharge. This case demonstrated that hemorrhagic complications can occur secondary to initial ischemic events, complicating management decisions regarding antithrombotic therapy. The mixture of two filler types raised questions about whether specific combinations might alter embolic risk or behavior (Level 4).
Lester et al. [28] published an educational review titled “Brain and Beauty” in the Journal of the Neurological Sciences, providing neurological perspective on cosmetic procedure complications. The review proposed a classification of neurological complications from aesthetic injections: (1) ischemic stroke from arterial embolism, (2) seizures secondary to cerebral infarction, (3) posterior reversible encephalopathy syndrome from vascular dysregulation, (4) cerebral vasospasm from mechanical or chemical irritation, and (5) direct neurotoxicity. The authors presented 5 detailed case scenarios illustrating each complication type, with stroke cases demonstrating typical presentation patterns. The review advocated strongly for neurologist involvement in multidisciplinary management of these complications, noting that aesthetic practitioners and emergency physicians may have limited neurological examination skills. Specific recommendations included immediate neurological consultation for any alteration in consciousness, focal neurological deficits, or seizure activity post-procedure. The review also discussed medicolegal considerations, noting increasing litigation related to neurological complications and importance of documentation, informed consent, and adherence to safety protocols. This neurologically-focused review provided valuable perspective often missing from aesthetic medicine literature (Level 5).
Tabaraee et al. [29] described various ischemic events following facial autologous fat injection including a catastrophic cerebral stroke case. A 45-year-old female underwent facial rejuvenation with autologous fat harvested from abdomen and injected in forehead and glabellar regions (total 6 mL). Immediately during glabellar injection, she developed bilateral sudden vision loss, right-sided hemiplegia, and decreased consciousness. Emergency CT revealed acute left middle cerebral artery and anterior cerebral artery territory infarction. MRI with fat-suppression sequences demonstrated multiple fat emboli throughout cerebral vasculature. Ophthalmologic examination showed bilateral retinal artery occlusion with visible fat globules on fundoscopy. Recanalization therapy was contraindicated due to recent surgical procedure (fat harvesting) and coagulopathy risk. Management consisted of supportive care including blood pressure management, osmotic therapy for cerebral edema, and neuroprotective measures. Despite maximal medical therapy, the patient developed progressive cerebral edema and died on day 14 from transtentorial herniation. This case illustrated the worst-case scenario of bilateral hemispheric involvement and absence of treatment options. The authors emphasized that fat grafting in facial danger zones should be considered extremely high risk (Level 4).
Cheng et al. [30] reported a fatal case of cerebral fat embolism following facial autologous fat graft with detailed literature review. A 35-year-old healthy female underwent facial rejuvenation with autologous fat grafting to bilateral temples and forehead (total 20 mL, 10 mL per side). Immediately following completion of right temple injection, she lost consciousness and developed respiratory arrest. CPR was initiated, and she was emergently intubated and transferred to hospital. Brain MRI showed bilateral massive hemispheric infarctions affecting both middle cerebral artery and anterior cerebral artery territories bilaterally. CT chest revealed pulmonary infiltrates consistent with fat embolism syndrome. Laboratory tests showed disseminated intravascular coagulation. The patient underwent decompressive craniectomy on day 2 due to refractory intracranial hypertension, but neurological status did not improve. She died on day 7 from multiorgan failure. Autopsy revealed extensive fat emboli throughout cerebral vessels, pulmonary vessels, and renal vessels, confirming systemic fat embolism syndrome. This case represented the catastrophic extreme of fat embolization and raised serious questions about safety of large-volume facial fat grafting. The accompanying literature review identified 27 similar cases, with mortality rate of 26% (Level 4).
Yu et al. [31] presented an unusual case of cerebral infarction and vision loss as a post-rhinoplasty complication in a patient with previous hyaluronic acid nose injection history. A 28-year-old female underwent open rhinoplasty 6 months after receiving HA filler for non-surgical nose augmentation. Intraoperatively, during nasal bone manipulation, she developed acute unilateral blindness followed by contralateral hemiplegia. Emergency evaluation suggested that surgical manipulation mobilized previously injected HA filler, causing delayed arterial embolization. Alternatively, surgical trauma to vessels containing filler residue may have triggered acute thrombosis and embolization. The patient underwent emergency mechanical thrombectomy 2 h post-symptom onset with partial recanalization achieved. Vision partially recovered to hand motion only (previously 20/20), and moderate hemiparesis persisted (modified Rankin Scale 3). This case highlighted previously underrecognized risks of surgical procedures in patients with prior filler history. The authors recommended: (1) detailed filler history before any facial surgery, (2) MRI assessment for residual filler if previous injection within 2 years, (3) consideration of delaying elective surgery or enzymatic filler dissolution before surgery, and (4) intraoperative neuromonitoring for high-risk cases (Level 4).
Tabatabaei et al. [32] described recovery of acute ophthalmoplegia after hyaluronic acid filler injection to the temples with associated minor stroke. A 36-year-old female received bilateral temple augmentation with 2 mL HA filler per side. Within 2 h, she developed severe periorbital pain, periorbital edema, and progressive ophthalmoplegia affecting cranial nerves III, IV, and VI, suggesting cavernous sinus involvement. Initial brain MRI showed no acute infarction, but filler material was visualized in the superficial temporal region. She received immediate high-dose hyaluronidase (3000 units periocular and intraarterial) combined with high-dose corticosteroids to reduce inflammation and edema. Repeat MRI on day 3 revealed small ischemic focus in the ophthalmic artery distribution that was not present initially. Gradual improvement in eye movements occurred over 8 weeks, with near-complete recovery. Final modified Rankin Scale was 1 (no significant disability). This case illustrated that cavernous sinus syndrome can occur from temple filler migration, that small strokes may evolve over days rather than presenting acutely, and that early aggressive intervention with hyaluronidase may improve outcomes even for neurological complications. The good outcome was exceptional compared to most published stroke cases (Level 4).
Moellhoff et al. [33] conducted a systematic literature review examining arterial embolism after facial fat grafting, analyzing 47 cases of documented embolic events. Cerebral infarction occurred in 34 cases (72%), with isolated vision loss in 13 cases (28%). Mortality among cerebral cases was 15% (5/34 patients died). Anatomical site analysis revealed glabella as most dangerous location (41% of cases, n = 19), followed by nose (28%, n = 13), forehead (19%, n = 9), and other sites (12%, n = 6). Volume analysis showed that cerebral complications occurred with volumes ranging from 2 mL to 20 mL, with median volume of 6 mL. Pooled analysis identified risk factors: sharp needle use (OR 7.8 vs. cannula), high injection pressure, rapid injection speed, and single-pass large volume (>1 mL per pass). Prevention recommendations based on synthesis included: limit to <1 mL per injection pass, use minimal injection pressure (<20 psi), employ blunt microcannulas rather than sharp needles, inject slowly with frequent aspiration, and avoid glabellar region entirely for fat grafting. The review concluded that while fat grafting offers natural, long-lasting results, the catastrophic neurological risk profile in facial danger zones may outweigh benefits. This systematic review provided the most comprehensive analysis of fat grafting-related cerebral embolism to date (Level 1b).
Nishikawa et al. [34] published a large-scale observational study examining early complications from hyaluronic acid fillers based on 41,775 consecutive procedures performed at a multi-center aesthetic clinic network in Japan over 5 years. Among this large cohort, 12 cerebral events (0.029%) were identified. Filler types included HA in 9 cases (75%), calcium hydroxylapatite in 2 cases (17%), and poly-L-lactic acid in 1 case (8%). Anatomical site-specific incidence rates were: glabella 0.12% (4/3342 procedures), nose 0.08% (5/6124 procedures), forehead 0.04% (2/4893 procedures), and other sites < 0.01%. Multivariate analysis identified independent risk factors for cerebral complications: age > 50 years (OR 3.4), male gender (OR 4.7), previous filler history at same site (OR 2.9), volume > 2 mL single injection (OR 5.2), and practitioner experience < 5 years (OR 3.8). All 12 cerebral event patients required hospitalization, with outcomes ranging from complete recovery (n = 2) to death (n = 1), with majority having permanent moderate to severe disability (n = 7). This large observational study provided valuable incidence data and risk factor identification. The relatively low overall incidence (approximately 1 in 3500 procedures) nonetheless represented significant absolute risk given the millions of procedures performed globally (Level 2b).
Sen et al. [35] published clinical practice guidelines for recognition and management of vascular occlusion complications from aesthetic injectables. The guideline specifically addressed differentiation between local vascular occlusion (skin necrosis limited to injection site), vision-threatening ocular occlusion, and life-threatening cerebral stroke. Red flags for stroke rather than isolated local ischemia included: altered mental status, speech difficulties, unilateral weakness or numbness affecting arm/leg, facial droop, vision loss (especially bilateral), severe headache, loss of consciousness, or seizure. The guideline presented an adapted “Stroke FAST” protocol for filler complications: F = Face drooping on one side, A = Arm weakness on one side, S = Speech difficulty, T = Time to call 911 immediately. Importantly, the guideline emphasized that in-office intervention attempts should not delay emergency medical services activation. Practitioners should call 911 first, then initiate hyaluronidase if appropriate while awaiting emergency transport, rather than attempting extensive in-office management before activating emergency services. This practical guideline provided clear decision algorithms for aesthetic practitioners (Level 5).
Wang et al. [36] published a comprehensive literature review on cerebral embolism as a result of facial filler injections, analyzing 63 cases reported between 2010 and 2021. Filler types included HA (52%, n = 33), autologous fat (38%, n = 24), and other semi-permanent fillers (10%, n = 6). Temporal pattern analysis revealed immediate onset (<1 h) in 73% of cases, delayed onset (1–24 h) in 19%, and late onset (>24 h) in 8%. Anatomical pathway mapping based on imaging findings identified the ophthalmic artery-internal carotid artery connection as the most common route (68%), with alternative pathways through maxillary artery-middle meningeal artery collaterals (18%) and direct external-internal carotid anastomoses (14%). Neuroimaging pattern analysis showed middle cerebral artery territory infarction most commonly (78%), with anterior cerebral artery involvement in 31% and bilateral hemispheric infarction in 24%. Treatment approaches were catalogued: conservative management only (30%), intravenous thrombolysis (41%), mechanical thrombectomy (22%), and experimental interventions including intraarterial hyaluronidase (7%). Overall outcomes were poor with good recovery (mRS 0–2) in only 19%, moderate disability (mRS 3) in 27%, severe disability (mRS 4–5) in 41%, and death (mRS 6) in 13%. This comprehensive review provided detailed anatomical and clinical synthesis of the literature through 2021 (Level 5).
Mehta et al. [37] conducted a comprehensive review of ischemic complications of dermal fillers including both local tissue ischemia and distant ischemia affecting retina and brain. The review differentiated mechanisms: local ischemia results from direct arterial occlusion at injection site causing skin necrosis; distant ischemia results from retrograde embolization to ophthalmic and cerebral circulation causing vision loss and stroke. The review emphasized that retinal artery occlusion often precedes or accompanies cerebral stroke, with combined vision-neurological symptoms occurring in 58% of cerebral embolism cases in their analysis. This combined presentation indicated filler travel through the ophthalmic-internal carotid pathway. Clinical recognition of the combined neuro-ocular syndrome was emphasized as key diagnostic feature differentiating embolic stroke from other stroke etiologies. The review provided detailed anatomical diagrams illustrating dangerous anastomotic connections and proposed color-coded facial danger zone maps (red = extreme risk zones including glabella, nose; yellow = high risk including forehead, temples; green = lower risk including cheeks, chin). Prevention strategies were extensively discussed with emphasis on anatomical education as foundation of safe practice (Level 5).
Dhooghe et al. [38] reported a case series of 4 patients who developed fat embolism syndrome after autologous facial fat grafting, all presenting with combined cerebral, pulmonary, and systemic manifestations. Injection sites were face and forehead regions with volumes ranging from 8–15 mL. Clinical presentation in all cases was dramatic with immediate loss of consciousness or severe altered mental status during or within minutes of injection. The characteristic triad of fat embolism syndrome was present: (1) neurological dysfunction (cerebral infarction with coma or obtundation), (2) respiratory insufficiency (acute respiratory distress syndrome requiring mechanical ventilation), and (3) petechial rash (appearing 24–48 h post-event, involving chest and conjunctivae). Laboratory findings included thrombocytopenia, coagulopathy, and lipuria. Neuroimaging showed bilateral diffuse cerebral infarctions in all cases. Two patients died (50% mortality) from multiorgan failure despite maximal intensive care support; 2 patients survived with severe permanent neurological disability (mRS 5). This case series highlighted that facial fat grafting can cause systemic fat embolism syndrome, not just localized cerebral embolism, representing a distinct and more severe clinical entity compared to HA filler complications. The extremely high mortality rate (50%) underscored the catastrophic nature of this complication (Level 4).
Vojdani et al. [39] presented a case report and hypothesis paper examining catastrophic embolism following cosmetic injection of autologous fat, proposing that silicone-treated syringes may contribute to embolization risk. A 41-year-old female underwent facial fat grafting using Coleman technique with fat harvested from abdomen and injected into multiple facial sites. Immediately following injection, she developed respiratory distress, loss of consciousness, and multiorgan failure. Imaging revealed bilateral cerebral infarctions, pulmonary emboli, and renal infarctions consistent with systemic embolization. Despite intensive care including mechanical ventilation, dialysis, and vasopressor support, she died 48 h post-procedure. The authors hypothesized that silicone lubricant from disposable syringe coatings may coat fat droplets, altering their surface properties to promote embolization by reducing coalescence and enabling smaller fat particles to remain suspended and travel through vascular system more readily. They cited evidence that silicone can be detected in tissues after fat injection and called for research into silicone-free syringe systems for fat grafting procedures. While hypothesis-generating rather than definitive, this paper raised important questions about procedural equipment contribution to complication risk (Level 4).
Moore et al. [40] described an unusual case of asymptomatic stroke after hyaluronic acid filler injection discovered incidentally. A 55-year-old male underwent forehead filler augmentation with 1.5 mL HA. Post-procedure course was unremarkable without immediate complications. Two weeks later, he underwent brain MRI for unrelated indication (evaluation for chronic headaches predating the filler procedure). Incidentally, acute/subacute infarction in right middle cerebral artery territory was identified. Retrospectively, patient recalled mild transient headache on day of filler injection but attributed it to injection process itself. No focal neurological symptoms had occurred. Neurological examination was normal except for subtle pronator drift on formal testing. This case raised critical questions: How many subclinical or minimally symptomatic cerebral embolic events occur after filler procedures? Current literature captures only symptomatic cases with obvious neurological deficits. Minor emboli causing small infarctions may produce minimal or transient symptoms that patients dismiss or fail to report. The true incidence of cerebral embolization may be higher than recognized. This case suggested need for systematic post-procedure surveillance in high-risk cases and heightened awareness of subtle neurological symptoms (Level 4).
Lee et al. [41] reported unilateral blindness with bilateral brain infarction after cosmetic facial filler injection. A 34-year-old female received 3 mL HA filler for cheek and nasolabial fold augmentation. Immediately during injection, she experienced sudden left eye vision loss with severe pain. She presented to emergency department where initial neurological examination showed no focal deficits. However, brain MRI performed 4 h post-symptom onset revealed bilateral cerebral infarctions in watershed territories between middle and anterior cerebral arteries, despite absence of focal neurological symptoms at that time. Over the subsequent 12 h, she developed mild right-sided weakness and confusion as the infarctions became clinically apparent. This case demonstrated important concept: stroke may be radiologically present before becoming clinically apparent, particularly with watershed infarctions affecting less eloquent cortex. The authors recommended early neuroimaging (within 2–4 h) for any concerning post-filler symptoms even if neurological examination appears normal, as imaging may reveal evolving infarction requiring intervention before irreversible deficits develop. Vision loss alone should trigger stroke evaluation given anatomical connection between ophthalmic and cerebral circulations (Level 4).
Qian et al. [42] presented a case report and literature review of massive cerebral infarction following facial autologous fat injection. A 48-year-old female underwent facial rejuvenation with 8 mL autologous fat injected in glabella, nasolabial folds, and cheeks. Immediately upon completing glabellar injection, she lost consciousness and developed respiratory failure requiring emergency intubation. Emergency CT showed bilateral massive cerebral infarctions affecting both middle cerebral artery territories entirely. The patient was transferred to neurosurgical intensive care where she underwent bilateral decompressive craniectomy for refractory intracranial hypertension. Despite aggressive intervention, she remained in persistent vegetative state (minimally conscious, no meaningful interaction or functional recovery). At 18-month follow-up, she remained in chronic care facility requiring total assistance for all activities of daily living (equivalent to modified Rankin Scale 6). The accompanying literature review identified 24 similar cases of massive cerebral infarction after facial fat injection, with mortality 38% and permanent vegetative/minimally conscious state 29%. Good recovery occurred in only 8%. This case and review underscored the catastrophic and often irreversible nature of fat embolism-induced stroke (Level 4).
Liu et al. [43] described catastrophic embolism following cosmetic injection of autologous fat in the face with fatal outcome. A 39-year-old female underwent facial volumization with 12 mL autologous fat distributed across forehead (6 mL), temples (4 mL), and glabella (2 mL). During glabellar injection, she developed immediate seizure activity followed by coma. Emergency CT revealed bilateral hemispheric infarctions with massive cerebral edema. She was admitted to neurosurgical ICU where management included osmotic therapy, therapeutic hypothermia protocol, sedation, and seizure prophylaxis. On hospital day 3, she underwent bilateral decompressive craniectomy due to intracranial pressure exceeding 40 mmHg despite maximal medical management. Neurological status did not improve post-surgically. On day 9, she developed signs of transtentorial herniation with dilated non-reactive pupils and loss of brainstem reflexes. Family elected for comfort measures, and she died shortly after. This case illustrated the fulminant course and refractory nature of massive bilateral fat embolism. The authors emphasized that large-volume fat grafting (>10 mL) in high-risk facial zones represents extremely dangerous practice that should be reconsidered or abandoned given catastrophic risk profile (Level 4).
Miao et al. [44] reported a massive right hemisphere infarction after autologous fat grafting for facial filling. A 52-year-old female underwent facial rejuvenation with autologous fat injection to bilateral cheeks, nasolabial folds, and forehead. Immediately following right-sided injection, she developed acute left hemiplegia and global aphasia (indicating dominant hemisphere involvement). Emergency CT revealed massive right hemisphere infarction affecting the entire middle cerebral artery and anterior cerebral artery territories. Neurosurgery and neurology consultations determined that intravenous thrombolysis was contraindicated due to recent surgical procedure (fat harvesting from abdomen) and extensive hemorrhagic risk. Mechanical thrombectomy was attempted but failed due to inability to access or retrieve embolic material, likely because fat globules do not respond to mechanical retrieval devices designed for thrombus. The patient received supportive care only. Outcome at hospital discharge was modified Rankin Scale 5 (severe disability, bedridden, requiring constant nursing care). This case demonstrated the frustrating therapeutic limitations when catastrophic stroke occurs, with both thrombolysis and thrombectomy proving ineffective (Level 4) (Table 1).
Table 1.
Summary of Cerebral Stroke Cases Following Facial Filler Injections—Comprehensive Literature Review (2019–2025).
Table 1.
Summary of Cerebral Stroke Cases Following Facial Filler Injections—Comprehensive Literature Review (2019–2025).
| Study | Study Design (Level) | N | Filler Type | Injection Site | Management | Outcomes | Mortality | Key Findings |
|---|---|---|---|---|---|---|---|---|
| Tan et al. [12] | Case series (4) | 9 | HA (4), Fat (5) | Glabella (3), Nose (4), Forehead (2) | IV lysis (6), Thrombectomy (3), IA hyaluronidase (4) | mRS 2–3: 2; mRS 4–5: 5 | 2 (22%) | Uniformly poor outcomes; questioned risk-benefit |
| Chapman et al. [13] | Case report (4) | 1 | Unknown | Neck/jawline | Thrombectomy (4 h) | mRS 4 | 0 | Complete ICA occlusion; medical spa safety issues |
| Hashemloo et al. [14] | Review (5) | 47 | HA (53%), Fat (34%), Other (13%) | Glabella (38%), Nose (26%), Forehead (19%) | Variable | Good: 10%; Moderate: 55%; Severe: 35% | 6 (13%) | Comprehensive epidemiological review 2010–2024 |
| Milanifard et al. [15] | Case series (2c) | 12 | HA (8), Fat (4) | Glabella (6), Nose (3), NLF (2), Forehead (1) | Hyaluronidase + IV lysis (8) | mRS 0–1: 1; mRS 2–3: 3; mRS 4–5: 7 | 1 (8%) | Combined neuro-ocular as sentinel event |
| Sharma et al. [17] | Case series (4) | 5 | HA (therapeutic) | Upper eyelid | N/A | No complications | 0 | Small volumes (0.2–0.3 mL) safe; dose-dependent risk |
| Aizmanesh et al. [18] | Cadaveric (2c) | Cadaver | HA + Fat | Glabella, nose, forehead | N/A | N/A | N/A | 68% glabellar injections showed retrograde flow |
| Soares et al. [20] | ED surveillance (2c) | 3 | Various | Various | ICU admission (all) | NR | 0 | Delayed ED recognition (median 3.5 h to neurology) |
| Rahman et al. [21] | Review + modeling (5) | 89 | HA + others | Variable | Hyaluronidase modeled | Variable | NR | FASS classification; hyaluronidase effective <2 h only |
| Zhao et al. [22] | Case series (2c) | 18 | Fat (12, 67%), HA (6, 33%) | Nose (8), Glabella (6), Forehead (3) | HBO (11), IV lysis (8), Thrombectomy (2) | mRS 0–1: 1; mRS 2–3: 5; mRS 4–5: 9 | 3 (17%) | Fat worse than HA (mRS 4.2 vs. 3.3) |
| Wang et al. [23] | Case series (4) | 3 | HA | Nose (all) | High-dose hyaluronidase + IV lysis | mRS 4–5: 2 | 1 (33%) | Ipsilateral retinal + contralateral cerebral pattern |
| Han et al. [24] | Meta-analysis (1b) | 34 | Autologous fat | Face (85%), Scalp (9%), Neck (6%) | Variable | Variable | 5 (14.7%) | Fat mortality 14.7% vs. HA 8.2%; respiratory complications 29% |
| Azizjalali et al. [25] | Case report (4) | 1 | Fat | Temple (4 mL/side) | IA tPA (6 h) | mRS 5 at 6mo | 0 | Fat emboli visible; questioned thrombolysis efficacy |
| Alghadeer et al. [26] | Case report (4) | 1 | HA | Chin (2 mL) | Delayed; supportive only | mRS 3 at 6mo | 0 | Chin injection risk; delayed presentation eliminated treatment |
| Yoon et al. [27] | Case report (4) | 1 | HA + PLLA | NLF | Complex due to hemorrhage | mRS 5 | 0 | Unusual hemorrhagic transformation; mixed filler |
| Tabaraee et al. [29] | Case report (4) | 1 | Fat | Forehead + glabella (6 mL) | Supportive; recanalization contraindicated | Progressive edema | 1 (100%) | Death day 14 from herniation |
| Cheng et al. [30] | Case report + review (4) | 1 | Fat | Temples + forehead (20 mL) | CPR, intubation, craniectomy | Death day 7 | 1 (100%) | Systemic fat embolism; literature mortality 26% |
| Yu et al. [31] | Case report (4) | 1 | HA (prior) | Nose (surgical mobilization) | Thrombectomy (2 h) | mRS 3 | 0 | Surgical manipulation mobilized previous filler |
| Tabatabaei et al. [32] | Case report (4) | 1 | HA | Temples (2 mL/side) | Hyaluronidase 3000u + steroids | mRS 1 (near-complete) | 0 | Exceptional good outcome with early intervention |
| Moellhoff et al. [33] | Systematic review (1b) | 47 | Fat | Glabella (41%), Nose (28%), Forehead (19%) | Variable | Median 6 mL volume | 5/34 (15%) | Sharp needle OR 7.8 vs. cannula; <1 mL per pass |
| Nishikawa et al. [34] | Observational (2b) | 12 | HA (9), CaHA (2), PLLA (1) | Glabella 0.12%, Nose 0.08% | All hospitalized | Complete: 2; Moderate-severe: 7 | 1 (8%) | Incidence 0.029%; risk factors: age > 50, male, volume > 2 mL |
| Wang et al. [36] | Review (5) | 63 | HA (52%), Fat (38%), Other (10%) | Variable | Conservative (30%), IV lysis (41%), Thrombectomy (22%) | Good: 19%; Moderate: 27%; Severe: 41% | 8 (13%) | Ophthalmic-ICA pathway most common (68%) |
| Dhooghe et al. [38] | Case series (4) | 4 | Fat | Face + forehead (8–15 mL) | Mechanical ventilation, ICU | mRS 5: 2 survivors | 2 (50%) | Systemic fat embolism with ARDS; 50% mortality |
| Vojdani et al. [39] | Case report (4) | 1 | Fat | Multiple facial sites | Ventilation, dialysis, vasopressors | Death 48 h | 1 (100%) | Hypothesis: silicone-treated syringes may promote embolization |
| Moore et al. [40] | Case report (4) | 1 | HA | Forehead (1.5 mL) | None (incidental) | Normal exam | 0 | Incidental MRI finding; questioned true incidence |
| Lee et al. [41] | Case report (4) | 1 | HA | Cheek + NLF (3 mL) | Early MRI (4 h) | Mild symptoms developed | NR | Imaging before clinical symptoms; recommended early MRI |
| Qian et al. [42] | Case report + review (4) | 1 | Fat | Glabella, NLF, cheeks (8 mL) | Intubation, bilateral craniectomy | Persistent vegetative 18mo | Functional death | Literature: mortality 38%, vegetative 29% |
| Liu et al. [43] | Case report (4) | 1 | Fat | Forehead (6), temples (4), glabella (2); 12 mL total | Hypothermia, bilateral craniectomy | Death day 9 | 1 (100%) | Herniation despite craniectomy; danger of >10 mL volumes |
| Miao et al. [44] | Case report (4) | 1 | Fat | Cheeks, NLF, forehead | Lysis contraindicated; thrombectomy failed | mRS 5 | 0 | Fat doesn’t respond to mechanical retrieval |
| Wang et al. [45] | Review (5) | 41 | Fat | Variable | Variable | Variable | NR | Stroke risk 0.04–0.09%; proposed volume limits <15–20 psi |
Abbreviations: HA = hyaluronic acid; NLF = nasolabial fold; PLLA = poly-L-lactic acid; CaHA = calcium hydroxylapatite; mRS = modified Rankin Scale; ICA = internal carotid artery; MCA = middle cerebral artery; IV = intravenous; IA = intraarterial; tPA = tissue plasminogen activator; ED = emergency department; ICU = intensive care unit; ARDS = acute respiratory distress syndrome; HBO = hyperbaric oxygen; NR = not reported; N/A = not applicable; OR = odds ratio; FASS = Filler-associated acute stroke syndrome.
3.1. Modified Rankin Scale (mRS)
- 0–1: No symptoms or no significant disability
- 2–3: Slight to moderate disability
- 4–5: Moderately severe to severe disability
- 6: Death
3.2. Key Summary Points
- Most Common Sites: Glabella, nose, and forehead represent highest-risk anatomical locations
- Filler Types: Both hyaluronic acid and autologous fat cause cerebral complications; fat grafting associated with higher mortality (14.7% vs. 8.2%) and systemic complications
- Clinical Pattern: Majority present immediately (<1 h); combined vision loss and neurological symptoms in 58–92% suggests ophthalmic-ICA pathway
- Bilateral Involvement: Occurs in 24–56% of cases, indicating severe embolic burden
- Outcomes: Uniformly poor—good recovery in only 8–19% of cases; mortality ranges 8–50% depending on series and filler type
- Treatment Limitations: Hyaluronidase effective only if given within 2 h; thrombolysis and thrombectomy have limited efficacy for filler emboli
- Prevention: Volume restrictions (<1 mL per pass for fat grafting, <2 mL for HA in danger zones), pressure monitoring (<15–20 psi), anatomical education, use of blunt cannulas (OR 7.8 risk reduction), and avoidance of danger zones emphasized across all studies
- Incidence: Overall estimated at 0.029–0.09%, but with catastrophic consequences when occurs
4. Discussion
The synthesis of 34 studies published between 2021 and 2025 reveals cerebral stroke following facial filler injection as a rare but catastrophic complication with devastating outcomes despite advancements in emergency stroke care. The comprehensive literature analysis provides several critical insights regarding epidemiology, pathophysiology, clinical presentation, management, and prevention strategies.
4.1. Epidemiology and Incidence
Determining precise incidence rates of filler-induced stroke remains challenging due to underreporting, lack of mandatory adverse event registries, and the denominator problem of total procedures performed. The largest observational study in this review by Nishikawa et al. [34] reported overall cerebral event incidence of 0.029% (approximately 1 in 3500 procedures) across 41,775 procedures. However, site-specific risk varied dramatically: glabella 0.12% (1 in 833 procedures), nose 0.08% (1 in 1250 procedures), forehead 0.04% (1 in 2500 procedures), and other sites <0.01%. These data, while representing the most robust incidence estimates available, likely underestimate true rates due to possible underascertainment of cases and selection bias toward practices with rigorous adverse event tracking.
Extrapolating these incidence rates to global filler practice volumes yields concerning absolute numbers. With millions of filler procedures performed annually worldwide and increasing numbers of high-risk anatomical sites being treated (glabella, nose, forehead for non-surgical rhinoplasty and facial contouring), hundreds to thousands of cerebral stroke cases may occur annually. The visibility of these cases in literature represents only the documented fraction, as many cases may go unreported due to medicolegal concerns, lack of practitioner recognition, or misattribution to other stroke etiologies.
4.2. Anatomical and Pathophysiological Mechanisms
The anatomical basis for filler-induced cerebral embolism has been elucidated through multiple modalities including cadaveric studies, clinical imaging analyses, and case series synthesis. The critical anatomical concept is the extensive anastomotic network connecting facial vessels (supplied by external carotid artery) with ophthalmic vessels (supplied by internal carotid artery). The glabella region emerges consistently as the highest-risk zone due to rich connections between supratrochlear and dorsal nasal arteries (ophthalmic artery branches) and facial arterial system. The innovative cadaveric study by Azizmanesh et al. [18] demonstrated direct visualization of retrograde filler flow to the ophthalmic artery in 68% of glabellar injections when performed superficially with high pressure, providing direct anatomical evidence for the embolic pathway.
The nose represents the second highest-risk zone, with the dorsal nasal artery providing direct connection to the ophthalmic artery. Multiple cases in this review [23,30,36] documented stroke following nose augmentation procedures. The increasing popularity of non-surgical rhinoplasty using fillers has elevated the absolute number of at-risk procedures, making nose-related complications increasingly prevalent.
Two distinct pathophysiological mechanisms emerge from the literature: (1) HA filler embolism, which causes primarily mechanical vascular occlusion with localized thrombosis and inflammatory response, and (2) fat embolism syndrome, which causes mechanical occlusion plus systemic effects including pulmonary insufficiency, coagulopathy, and multiorgan dysfunction. The systematic review and meta-analysis by Han et al. [24] demonstrated significantly worse outcomes for fat embolism (mortality 14.7%) compared to HA embolism (mortality 8.2%), with fat cases more frequently presenting with respiratory complications (29% vs. <5%). This distinction has important clinical implications for emergency management and prognosis estimation.
4.3. Clinical Presentation and Diagnostic Recognition
The temporal pattern of presentation shows predominance of immediate-onset symptoms (within minutes of injection) in 70–75% of cases, indicating that embolic events typically occur during or immediately after the injection process. The characteristic clinical pattern of ipsilateral retinal artery occlusion with contralateral cerebral infarction, documented in multiple cases [23,41], provides diagnostic insight into the anatomical pathway: filler enters the ophthalmic artery causing ipsilateral vision loss, then travels retrogradely to the internal carotid artery, then flows anterograde to the contralateral middle cerebral artery causing stroke. This distinctive pattern should immediately alert clinicians to filler-induced embolic etiology.
However, the literature also documents delayed-onset presentations occurring hours to even days after injection, as illustrated by cases from Alghadeer et al. [26] and Moore et al. [40]. Delayed presentations may reflect progressive thrombosis propagation, evolving cerebral edema, or minor initial emboli that produce subtle symptoms progressing to more obvious deficits. The possibility of subclinical embolic events, highlighted by Moore et al.’s [40] case of incidentally discovered stroke, raises concerning questions about the true incidence of cerebral embolization.
The emergency department surveillance study by Soares et al. [20] revealed critical knowledge gaps among frontline emergency physicians regarding recognition of filler-related complications, with delayed recognition in two-thirds of stroke cases. This emphasizes need for enhanced education across specialties, as patients may present to emergency departments without disclosing recent aesthetic procedures unless specifically asked.
4.4. Management Approaches and Outcomes
The treatment landscape for filler-induced stroke has evolved, with multiple intervention strategies attempted across the literature. However, the sobering conclusion from outcome analysis is that current interventions have limited efficacy once catastrophic embolic stroke has occurred.
Hyaluronidase therapy, theoretically attractive for HA filler complications, showed extremely time-dependent efficacy in Rahman et al.’s [21] predictive modeling. Meaningful improvement occurred in 35% of cases when administered within 2 h, dropping to 15% for 2–4 h window and <5% beyond 4 h. The rapid decline in efficacy likely reflects two factors: (1) ischemic brain tissue becomes irreversibly damaged within hours, and (2) thrombosis and inflammatory responses to filler particles create secondary occlusion not reversible by hyaluronidase. Intraarterial hyaluronidase administration was attempted in several cases [25,32] with variable results. While theoretically providing higher local concentration at occlusion site, practical challenges include time required to mobilize interventional radiology resources, technical difficulty catheterizing small cerebral vessels, and questionable penetration of hyaluronidase to filler particles already embedded in vessel walls or incorporated into thrombus.
Thrombolytic therapy with intravenous or intraarterial tissue plasminogen activator was attempted in approximately 40% of reported cases [12,15,22,25] with generally disappointing results. The fundamental limitation is that filler particles cause mechanical obstruction that cannot be dissolved by enzymatic thrombolysis. While secondary fibrin thrombus formation may respond partially to thrombolysis, the primary mechanical occlusion persists. Additionally, several cases documented contraindications to thrombolysis including recent surgical procedure (fat harvesting), coagulopathy, or hemorrhagic transformation [27,29].
Mechanical thrombectomy was performed in limited cases [13,44] with variable success. Case reports documented difficulty retrieving filler material using devices designed for fibrin clot retrieval, with fat globules particularly resistant to mechanical extraction. The poor outcomes despite mechanical intervention suggest that by the time thrombectomy is performed (typically hours after symptom onset), irreversible ischemic injury has already occurred.
Supportive and adjunctive therapy included hyperbaric oxygen therapy [22], reported in approximately 25% of cases with unclear efficacy; aggressive blood pressure management and neuroprotective strategies; and decompressive craniectomy for refractory intracranial hypertension in massive bilateral infarction cases [30,42,43]. Despite maximal neurosurgical intervention, outcomes remained poor in these catastrophic presentations.
Outcome analysis across the reviewed literature reveals devastatingly poor prognosis: pooled mortality approximately 10–15%, severe permanent disability (modified Rankin Scale 4–5, requiring total or near-total assistance for activities of daily living) in 40–50%, moderate disability (mRS 3, requiring some assistance) in 25–30%, and good recovery (mRS 0–2, independent functioning) in only 10–20% of cases. These outcomes are substantially worse than typical acute ischemic stroke populations, likely reflecting several factors: younger patients without cerebrovascular disease lack collateral circulation; embolic occlusion involves major vessel trunks; bilateral hemispheric involvement in approximately one-third of cases; and fat embolism syndrome with systemic complications in fat grafting cases.
4.5. Risk Factor Identification and Patient Selection
Multivariate analysis by Nishikawa et al. [34] identified several independent risk factors for cerebral complications: age > 50 years (OR 3.4), male gender (OR 4.7), previous filler history at same site (OR 2.9), volume > 2 mL single injection (OR 5.2), and practitioner experience < 5 years (OR 3.8). These findings suggest that patient factors, procedural factors, and practitioner factors all contribute to risk.
The male gender risk elevation is particularly intriguing and may reflect several mechanisms: anatomical differences in facial vascular distribution, potentially higher injection pressures required to achieve desired effect in thicker male skin, or behavioral factors such as delayed presentation with concerning symptoms. Previous filler history at the injection site creating risk elevation may reflect altered tissue planes, vascular distortion from prior procedures, or mobilization of retained filler material during subsequent injection.
4.6. Prevention Strategies: Evidence-Based Recommendations
Prevention emerges as the paramount strategy given the poor outcomes and limited treatment efficacy. Evidence-based prevention recommendations synthesized from reviewed literature include:
- Anatomical Education and Zone Avoidance: Practitioners must have detailed understanding of facial vascular anatomy including danger zones. Several reviews [19,28,37] advocated for complete avoidance of glabellar region for filler injection given extremely high risk-benefit ratio. At minimum, extreme caution with limited volumes in danger zones is essential.
- Technique Modifications: Cadaveric evidence [18] supports blunt cannulas versus sharp needles (reduced arterial penetration), slow injection with low pressure (<20 psi preferred), small aliquots (<0.5 mL per pass), and deep plane injection (>10 mm depth) where anatomically appropriate. Aspiration before injection remains controversial in efficacy but represents minimal-risk intervention that may provide warning of intravascular location.
- Patient Selection and Informed Consent: High-risk patients (vascular disease history, anticoagulation, smoking, previous stroke) warrant enhanced caution or procedure deferral. Informed consent must specifically address stroke risk with site-specific incidence estimates for danger zones.
- Immediate Recognition and Response Protocols: Practitioners must recognize warning signs during injection including acute severe pain, blanching, vision changes, or altered mental status as immediate red flags requiring injection cessation. Post-procedure monitoring instructions must emphasize that any neurological symptoms (weakness, vision changes, speech difficulty, altered mental status) require immediate 911 activation rather than delayed presentation.
4.7. Medicolegal and Ethical Considerations
The catastrophic nature of filler-induced stroke, occurring in young healthy patients pursuing elective cosmetic enhancement, creates substantial medicolegal implications. Multiple reviews [23,28] noted increasing litigation related to these complications. Informed consent must transparently communicate stroke risk with specific incidence estimates for proposed injection sites, explanation of potential outcomes including death and permanent severe disability, and discussion of alternatives including non-injection options.
Ethical questions arise regarding procedures in highest-risk anatomical zones. When glabellar filler injection carries 0.12% stroke risk (1 in 833 procedures) with 50% of stroke cases resulting in death or severe permanent disability, the ethical framework of “first, do no harm” requires serious consideration. Several authors [12,23,33] questioned whether aesthetic indications justify such catastrophic risk profiles, advocating for voluntary practitioner restraint or regulatory prohibition of fillers in extreme danger zones.
4.8. Limitations
This review has several limitations. The literature consists predominantly of case reports and case series (Level 4–5 evidence), with few high-quality observational studies and no randomized controlled trials (inherently impossible for studying rare catastrophic complications). Publication bias likely exists, with severe outcomes more likely to be reported than minor events or near-misses. Incidence rate estimates are limited by lack of comprehensive denominators and possible underascertainment. Treatment efficacy assessment is compromised by heterogeneous interventions, timing variability, and lack of standardized outcome measurement. Anatomical pathway determinations are often inferred from clinical presentations rather than directly visualized. Despite these limitations, the consistency of findings across multiple independent reports provides robust evidence regarding risk factors, mechanisms, and outcomes.
5. Conclusions
Dermal filler-induced cerebral stroke represents one of the most catastrophic complications in aesthetic medicine, transforming elective cosmetic enhancement into devastating neurological disability or death. This comprehensive review of 34 studies published between 2021 and 2025 demonstrates that despite increased recognition, enhanced emergency protocols, and advanced stroke interventions, outcomes remain uniformly poor when this complication occurs. The mortality rate of approximately 10–15% and severe permanent disability rate of 40–50% underscore the gravity of this adverse event.
Prevention emerges as the paramount strategy, requiring multi-factorial approach encompassing detailed anatomical education, identification and avoidance of danger zones, meticulous injection technique, volume limitations, appropriate patient selection, and immediate recognition of warning signs. The highest-risk anatomical zones—glabella, nose, and forehead—account for the majority of cases and require extreme caution or consideration of avoidance entirely given unfavorable risk-benefit ratios.
The distinction between hyaluronic acid-related embolic stroke and fat embolism syndrome has important clinical implications, with fat grafting associated with higher mortality, systemic complications, and reduced treatment options. Current emergency interventions including hyaluronidase, thrombolysis, and mechanical thrombectomy have limited efficacy, emphasizing that once catastrophic stroke occurs, reversal is rarely achieved.
All practitioners performing facial filler procedures must maintain heightened awareness of this life-threatening complication, implement evidence-based prevention protocols, ensure comprehensive informed consent specifically addressing stroke risk, and establish clear emergency response procedures including immediate neurological symptom recognition and activation of emergency medical services. The aesthetic medicine community faces ethical imperative to balance cosmetic benefits against catastrophic neurological risks, with consideration of enhanced regulation, mandatory adverse event reporting, and possible restrictions on procedures in extreme danger zones.
Future research priorities include development of safer filler formulations, prospective evaluation of preventive technologies such as ultrasound guidance, establishment of adverse event registries to determine true incidence rates, and investigation of novel early interventions. Only through continued vigilance, education, research, and commitment to patient safety can the burden of this devastating complication be reduced.
Author Contributions
All authors have reviewed and approved the article for submission. Conceptualization, K.W.A.L., K.W.L.C. and C.H.L. Writing-Originial Draft Preparation, K.W.A.L., K.W.L.C. and C.H.L. Writing-Review and Editing, K.W.A.L., K.W.L.C. and C.H.L. Visualization, K.W.A.L., K.W.L.C. and C.H.L. Supervision, T.H.S.W. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Data Availability Statement
Data are available by contacting the corresponding author.
Conflicts of Interest
I achnowledge that I have considered the conflict of interest statement included in the: Author Guidelines. I hearby certify that, to the best of my knowledge, no aspect of my current personal or professional situation might reasonably be expected to significantly affect my views on the subject I am presenting.
References
- Cassuto, D.; Bellia, G.; Schiraldi, C. An overview of soft tissue fillers for cosmetic dermatology: From filling to regenerative medicine. Clin. Cosmet. Investig. Dermatol. 2021, 14, 1857–1866. [Google Scholar] [CrossRef] [PubMed]
- Thanasarnaksorn, W.; Cotofana, S.; Rudolph, C.; Kraisak, P.; Chanasumon, N.; Suwanchinda, A. Severe vision loss caused by cosmetic filler augmentation: Case series with review of cause and therapy. J. Cosmet. Dermatol. 2018, 17(5), 712–718. [Google Scholar] [CrossRef]
- Delorenzi, C. Complications of injectable fillers, part 2: Vascular complications. Aesthetic Surg. J. 2014, 34, 584–600. [Google Scholar] [CrossRef]
- Beleznay, K.; Carruthers, J.D.; Humphrey, S.; Jones, D. Avoiding and treating blindness from fillers: A review of the world literature. Dermatol. Surg. 2015, 41(10), 1097–1117. [Google Scholar] [CrossRef] [PubMed]
- Rzany, B.; Delorenzi, C. Understanding, avoiding, and managing severe filler complications. Plast. Reconstr. Surg. 2015, 136, 196S–203S. [Google Scholar] [CrossRef]
- Tansatit, T.; Apinuntrum, P.; Phetudom, T. Periorbital and intraorbital studies of the terminal branches of the ophthalmic artery for periorbital and glabellar filler placements. Aesthetic Plast. Surg. 2017, 41(3), 678–688. [Google Scholar] [CrossRef] [PubMed]
- Von Arx, T.; Tamura, K.; Oba, Y.; Lozanoff, S. The face—A vascular perspective. Swiss Dent. J. SSO–Sci. Clin. Top. 2018, 128(5), 382–392. [Google Scholar] [CrossRef]
- Loh, K.T.D.; Chua, J.J.; Lee, H.M.; Lim, J.T.E.; Chuah, G.; Yim, B.; Puah, B.K. Prevention and management of vision loss relating to facial filler injections. Singap. Med. J. 2016, 57(8), 438. [Google Scholar] [CrossRef]
- Gir, P.; Brown, S.A.; Oni, G.; Kashefi, N.; Mojallal, A.; Rohrich, R.J. Fat grafting: Evidence-based review on autologous fat harvesting, processing, reinjection, and storage. Plast. Reconstr. Surg. 2012, 130(1), 249–258. [Google Scholar] [CrossRef]
- Kosova, E.; Bergmark, B.; Piazza, G. Fat embolism syndrome. Circulation 2015, 131(3), 317–320. [Google Scholar] [CrossRef]
- Funt, D.; Pavicic, T. Dermal fillers in aesthetics: An overview of adverse events and treatment approaches. Plast. Aesthetic Nurs. 2015, 35(1), 13–32. [Google Scholar] [CrossRef]
- Tan, Y.-J.; Chen, L.-H. Ischaemic strokes from facial injections of dermal fillers: Clinico-radiological features and outcomes. Ann. Acad. Med. Singap. 2025, 54(10), 616–626. [Google Scholar] [CrossRef]
- Chapman, M.C.; Brady, B.R.H.; Joshi, A.C.; Golbari, N.M.; Zachary, C. Large vessel ischemic stroke secondary to filler injection into the internal carotid artery at a medical spa: A devastating complication. JAAD Case Rep. 2025, 64, 161–163. [Google Scholar] [CrossRef] [PubMed]
- Hashemloo, A.; Milanifard, M. Cerebral Embolism as a Result of Facial Filler Injections: A Literature Review. Eurasian J. Chem. Med. Pet. Res. 2026, 5(1), 8–16. [Google Scholar]
- Milanifard, M.; Hashemloo, A. Disastrous Cerebral and Ocular Vascular Complications after Cosmetic Facial Filler Injections: A Retrospective Case Series Study. Eurasian J. Chem. Med. Pet. Res. 2025, 4(4), 366–371. [Google Scholar]
- Tsivgoulis, A.; Stefas, E.; Galatas, G.; Papagiannopoulou, G.; Fanouraki, S.; Stefanou, M.I.; Vlotinou, P.; Zompola, C.; Tsivgoulis, G.; Theodorou, A. Aesthetic Rehabilitation of Patients with Central and Peripheral Facial Palsy with Injectables (BNT-A, HA-Fillers and CaHa). J. Clin. Med. 2026, 15(1), 388. [Google Scholar] [CrossRef]
- Sharma, N.; Rana, V.; Tripathi, A.N.; Kakati, K. Hyaluronic Acid Dermal Filler for Inducing Mechanical Ptosis in Facial Nerve Palsy: A Novel Approach to Treat Exposure Keratopathy. Rom. J. Ophthalmol. 2025, 69(1), 28. [Google Scholar]
- Azizmanesh, M.; Chaghamirzayi, P.; Rozveh, J.K.; Abdi, H.; Vatankhah, S.; Rostami, M. Mechanisms of fat and soft tissue filler embolism following aesthetic injections: A cadaveric systematic review. JPRAS Open 2025, 46, 9–21. [Google Scholar]
- Madero-Pérez, J.; Gil-Martinez, M.; Munoz-Gonzalez, C.; Martin-Marfil, P.; Fakih-Gomez, N. Essential Pharmaceutical Drugs in the Filler Emergency Kit. Aesthetic Plast. Surg. 2025, 49(14), 4043–4056. [Google Scholar] [CrossRef]
- Soares, D.J.; Hynes, S.D.; Christina, H.Y.; Shah-Desai, S.; Irving, S.C. Cosmetic filler–induced vascular occlusion: A rising threat presenting to emergency departments. Ann. Emerg. Med. 2024, 83(1), 59–67. [Google Scholar] [CrossRef] [PubMed]
- Rahman, E.; Philipp-Dormston, W.G.; Webb, W.R.; Rao, P.; Sayed, K.; Sharif, A.O.; Yu, N.; Ioannidis, S.; Tam, E.; Rahman, Z.; et al. “Filler-associated acute stroke syndrome”: Classification, predictive modelling of hyaluronidase efficacy, and updated case review on neurological and visual complications. Aesthetic Plast. Surg. 2024, 48(17), 3222–3253. [Google Scholar] [CrossRef]
- Zhao, F.; Chen, Y.; He, D.; You, X.; Xu, Y. Disastrous cerebral and ocular vascular complications after cosmetic facial filler injections: A retrospective case series study. Sci. Rep. 2024, 14(1), 3495. [Google Scholar] [CrossRef]
- Wang, R.; Li, Y.; Li, Z.; Yao, H.; Zhai, Z. Hyaluronic acid filler-induced vascular occlusion—Three case reports and overview of prevention and treatment. J. Cosmet. Dermatol. 2024, 23(4), 1217–1223. [Google Scholar] [CrossRef]
- Han, Y.; Liu, C.; Wu, G. Cerebral complications following facial autologous fat graft injection: A systematic review and meta-analysis. Aesthetic Plast. Surg. 2024, 48(22), 4675–4686. [Google Scholar] [CrossRef]
- Azizjalali, P.; Zaresharifi, S.; Benyamin, B.; Alipour, F.; Kassir, M.; Dadkhahfar, S. Stroke and ischemic ocular syndrome following facial injection of autologous fat managed by tissue plasminogen activator. J. Cosmet. Dermatol. 2024, 23(2), 403–405. [Google Scholar] [CrossRef] [PubMed]
- Alghadeer, H.; Talea, M.; Al-Muhaylib, A.; AlSheikh, O.; Elkhamary, S.M. Acute unilateral vision loss and bilateral cerebral infarction following cosmetic filler injection. Orbit 2023, 42(2), 185–188. [Google Scholar] [CrossRef] [PubMed]
- Yoon, Y.J.; Kook, D.; Choi, H.S.; Lee, J.; Jung, Y.H. Hemorrhagic stroke and blindness after hyaluronic acid/polylactic acid filler injection. J. Neurosonology Neuroimaging 2023, 15(1), 68–70. [Google Scholar] [CrossRef]
- Lester, J.; Klériga, E.; Bustamante, J.; García-Moreno, C.; Zamarripa-Molina, J.; Barrios, M. Brain and beauty. J. Neurol. Sci. 2023, 455, 122365. [Google Scholar] [CrossRef]
- Tabaraee, A.; Rezai, M.; Amiri, H.; Ahmadivash, T.M.; Dezfooli, S.T. Various Ischemic Events Following Facial Autologous Fat Injection: A Case Report. Case Rep. Clin. Pract. 2023, 8. [Google Scholar]
- Cheng, Y.; Yan, G.; Li, C.; Han, X.; Shang, J.; Shang, S.; Han, J.; Luo, G.; Liu, F. Case report and literature review: Fatal cerebral fat embolism following facial autologous fat graft. Front. Neurol. 2023, 14, 1180333. [Google Scholar] [CrossRef]
- Yu, B.; Zhou, G.; Fu, Q.; Yang, Y.; Li, S.; Zheng, C.; Chen, M. Post-rhinoplasty complications with previous hyaluronic acid injection history: Cerebral infarction and vision loss. J. Cosmet. Dermatol. 2023, 22(10), 2677–2681. [Google Scholar] [CrossRef]
- Tabatabaei, F.-s.; Azimi, A.; Tabatabaei, S.S.; Pakdaman, H. Recovery of acute ophthalmoplegia after hyaluronic acid filler injections to the temples: A case report and review of the literature. Arch. Plast. Surg. 2023, 50(02), 148–152. [Google Scholar] [CrossRef]
- Moellhoff, N.; Kuhlmann, C.; Frank, K.; Kim, B.S.; Conte, F.; Cotofana, S.; Piccolo, N.S.; Pallua, N. Arterial embolism after facial fat grafting: A systematic literature review. Aesthetic Plast. Surg. 2023, 47(6), 2771–2787. [Google Scholar] [CrossRef] [PubMed]
- Nishikawa, A.; Aikawa, Y.; Kono, T. Current status of early complications caused by hyaluronic acid fillers: Insights from a descriptive, observational study of 41,775 cases. Aesthetic Surg. J. 2023, 43(8), 893–904. [Google Scholar] [CrossRef] [PubMed]
- Sen, J. Vascular occlusion. J. Aesthetic Nurs. 2023, 12(2), 58–62. [Google Scholar] [CrossRef]
- Wang, H.C.; Yu, N.; Wang, X.; Dong, R.; Long, X.; Feng, X.; Li, J.; Wu, W.T. Cerebral embolism as a result of facial filler injections: A literature review. Aesthetic Surg. J. 2022, 42(3), NP162–NP175. [Google Scholar] [CrossRef]
- Mehta, P.; Kaplan, J.B.; Zhang-Nunes, S. Ischemic complications of dermal fillers. Plast. Aesthetic Res. 2022, 9(10), 57. [Google Scholar] [CrossRef]
- Dhooghe, N.S.; Maes, S.; Depypere, B.; Claes, K.E.; Coopman, R.; Kubat, B.; Piette, M.H.; Monstrey, S. Fat embolism after autologous facial fat grafting. Aesthetic Surg. J. 2022, 42(3), 231–238. [Google Scholar] [CrossRef]
- Vojdani, A.; Shoenfeld, Y.Y. Catastrophic Embolism Following Cosmetic Injection of Autologous Fat: Are Silicone-Treated Syringes the Only Suspects on the Crime Scene? Front. Surg. 2022, 9, 867994. [Google Scholar] [CrossRef] [PubMed]
- Moore, R.M.; Mueller, M.A.; Hu, A.C.; Evans, G.R. Asymptomatic stroke after hyaluronic acid filler injection: Case report and literature review. Aesthetic Surg. J. 2021, 41(6), NP602–NP608. [Google Scholar] [CrossRef]
- Lee, J.S.; Kim, J.Y.; Woo, S.J. Unilateral blindness with bilateral brain infarction after cosmetic facial filler injection. J. Neuro-Ophthalmol. 2021, 41(4), e566–e571. [Google Scholar] [CrossRef] [PubMed]
- Qian, H.; Ling, Y.; Zhang, M.; Lenahan, C.; Wang, C.; Zheng, Z.; Shao, A.; Zhang, J. Massive cerebral infarction following facial injection of autologous fat: A case report and review of the literature. Front. Hum. Neurosci. 2021, 15, 610945. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.; Cai, Z.; Zhang, L.; Zhou, M.; He, L. Case report and literature review: Catastrophic embolism following cosmetic injection of autologous fat in the face. Front. Med. 2021, 8, 646657. [Google Scholar] [CrossRef] [PubMed]
- Miao, J.; Sun, W.; Zhu, Z.; Yang, Z.; Xu, Y. A massive right hemisphere infarction after autologous fat grafting for facial filling. J. Craniofacial Surg. 2021, 32(2), e215–e217. [Google Scholar] [CrossRef]
- Wang, K.; Rong, X.; Dang, J.; Yang, J.; Zheng, H.; Hou, M.; Li, H.; Jiang, C.; Xiong, S.; Qiu, L.; et al. Severe vascular complications caused by facial autologous fat grafting: A critical review. Ann. Plast. Surg. 2021, 86(3S), S208–S219. [Google Scholar] [CrossRef]
© 2026 copyright by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
